Vertex Pharma (VRTX) Tops Q1 EPS by 4c; Reiterates Outlook
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $546.12 -2.12%
EPS Growth %: 0.0%
Financial Fact:
Restructuring expense: 8K
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Restructuring expense: 8K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $3.52, $0.04 better than the analyst estimate of $3.48. Revenue for the quarter came in at $2.1 billion versus the consensus estimate of $2.07 billion.
GUIDANCE:
Vertex Pharma reiterates FY2022 revenue of $8.4-8.6 billion, versus the consensus of $8.58 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
- Dell’s earning report was bullish for Intel CPU demand, analyst says
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
